Activation of the viral sensor oligoadenylate synthetase 2 (Oas2) prevents pregnancy-driven mammary cancer metastases.
Ho, W-HJ
Law, AMK
Masle-Farquhar, E
Castillo, LE
Mawson, A
O'Bryan, MK
Goodnow, CC
Gallego-Ortega, D
Oakes, SR
Ormandy, CJ
- Publisher:
- BMC
- Publication Type:
- Journal Article
- Citation:
- Breast Cancer Res, 2022, 24, (1), pp. 31
- Issue Date:
- 2022-05-03
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Ho, W-HJ | |
dc.contributor.author | Law, AMK | |
dc.contributor.author | Masle-Farquhar, E | |
dc.contributor.author | Castillo, LE | |
dc.contributor.author | Mawson, A | |
dc.contributor.author | O'Bryan, MK | |
dc.contributor.author | Goodnow, CC | |
dc.contributor.author | Gallego-Ortega, D | |
dc.contributor.author | Oakes, SR | |
dc.contributor.author | Ormandy, CJ | |
dc.date.accessioned | 2023-02-27T19:11:27Z | |
dc.date.available | 2022-04-11 | |
dc.date.available | 2023-02-27T19:11:27Z | |
dc.date.issued | 2022-05-03 | |
dc.identifier.citation | Breast Cancer Res, 2022, 24, (1), pp. 31 | |
dc.identifier.issn | 1465-5411 | |
dc.identifier.issn | 1465-542X | |
dc.identifier.uri | http://hdl.handle.net/10453/166464 | |
dc.description.abstract | BACKGROUND: The interferon response can influence the primary and metastatic activity of breast cancers and can interact with checkpoint immunotherapy to modulate its effects. Using N-ethyl-N-nitrosourea mutagenesis, we found a mouse with an activating mutation in oligoadenylate synthetase 2 (Oas2), a sensor of viral double stranded RNA, that resulted in an interferon response and prevented lactation in otherwise healthy mice. METHODS: To determine if sole activation of Oas2 could alter the course of mammary cancer, we combined the Oas2 mutation with the MMTV-PyMT oncogene model of breast cancer and examined disease progression and the effects of checkpoint immunotherapy using Kaplan-Meier survival analysis with immunohistochemistry and flow cytometry. RESULTS: Oas2 mutation prevented pregnancy from increasing metastases to lung. Checkpoint immunotherapy with antibodies against programmed death-ligand 1 was more effective when the Oas2 mutation was present. CONCLUSIONS: These data establish OAS2 as a therapeutic target for agents designed to reduce metastases and increase the effectiveness of checkpoint immunotherapy. | |
dc.format | Electronic | |
dc.language | eng | |
dc.publisher | BMC | |
dc.relation.ispartof | Breast Cancer Res | |
dc.relation.isbasedon | 10.1186/s13058-022-01525-z | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | 1112 Oncology and Carcinogenesis | |
dc.subject.classification | Oncology & Carcinogenesis | |
dc.subject.mesh | 2',5'-Oligoadenylate Synthetase | |
dc.subject.mesh | Adenine Nucleotides | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Breast Neoplasms | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Interferons | |
dc.subject.mesh | Ligases | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Oligoribonucleotides | |
dc.subject.mesh | Pregnancy | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Breast Neoplasms | |
dc.subject.mesh | Ligases | |
dc.subject.mesh | 2',5'-Oligoadenylate Synthetase | |
dc.subject.mesh | Interferons | |
dc.subject.mesh | Oligoribonucleotides | |
dc.subject.mesh | Adenine Nucleotides | |
dc.subject.mesh | Pregnancy | |
dc.subject.mesh | Female | |
dc.title | Activation of the viral sensor oligoadenylate synthetase 2 (Oas2) prevents pregnancy-driven mammary cancer metastases. | |
dc.type | Journal Article | |
utslib.citation.volume | 24 | |
utslib.location.activity | England | |
utslib.for | 1112 Oncology and Carcinogenesis | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering | |
pubs.organisational-group | /University of Technology Sydney/Centre for Health Technologies (CHT) | |
utslib.copyright.status | open_access | * |
dc.date.updated | 2023-02-27T19:11:26Z | |
pubs.issue | 1 | |
pubs.publication-status | Published online | |
pubs.volume | 24 | |
utslib.citation.issue | 1 |
Abstract:
BACKGROUND: The interferon response can influence the primary and metastatic activity of breast cancers and can interact with checkpoint immunotherapy to modulate its effects. Using N-ethyl-N-nitrosourea mutagenesis, we found a mouse with an activating mutation in oligoadenylate synthetase 2 (Oas2), a sensor of viral double stranded RNA, that resulted in an interferon response and prevented lactation in otherwise healthy mice. METHODS: To determine if sole activation of Oas2 could alter the course of mammary cancer, we combined the Oas2 mutation with the MMTV-PyMT oncogene model of breast cancer and examined disease progression and the effects of checkpoint immunotherapy using Kaplan-Meier survival analysis with immunohistochemistry and flow cytometry. RESULTS: Oas2 mutation prevented pregnancy from increasing metastases to lung. Checkpoint immunotherapy with antibodies against programmed death-ligand 1 was more effective when the Oas2 mutation was present. CONCLUSIONS: These data establish OAS2 as a therapeutic target for agents designed to reduce metastases and increase the effectiveness of checkpoint immunotherapy.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph